Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
By Matthew Harrington, Global Head, Clinical Product, Syneos Health | Artificial intelligence (AI) now features prominently ...
TEL AVIV, Israel, May 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and ...
InvestorsHub on MSN
CytomX highlights clinical progress for lead cancer drug in Q4 update
CytomX Therapeutics Inc. (NASDAQ:CTMX) used its fourth-quarter 2025 earnings call to highlight progress in the clinical ...
Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...
12d
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...
UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V. today announced an updated clinical development strategy to evaluate ilofotase alfa in two indications. The company’s proprietary compound ...
Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala ...
TAIPEI and SAN DIEGO, March 18, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...
Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results